NCI scientists, from postdoctoral fellows to principal investigators, discuss various topics including their personal backgrounds, how they came to be in the field of cancer research, their current projects, and a look to the future of medical oncology.
Menu Contact Dictionary Search. Questions to Ask about Your Diagnosis. Types of Cancer Treatment. A to Z List of Cancer Drugs. Questions to Ask about Your Treatment. Questions to Ask About Cancer. Talking about Your Advanced Cancer. Planning for Advanced Cancer. Advanced Cancer and Caregivers.
Questions to Ask about Advanced Cancer. Finding Health Care Services. Adolescents and Young Adults with Cancer. Join the Cause Other Ways to Give. Let's spread the word about Immunotherapy! Click to share this page with your community. Contact Us We are happy to help you through a cause marketing campaign, including legal language and promotional strategies. Better Business Bureau Cause-Related Marketing Guidelines source Clearly disclose how the charity benefits from the sale of products or services i.
These promotions have involved a variety of goods and services including breakfast cereals, clothing, cosmetics, credit cards, long distance phone calls, and fast-food. Placement of the disclosure might be, for example, within the product advertisement that features the charity benefit, on the product packaging, on the hangtag attached to the product, or on the catalog order form.
A study in mice sheds light onto how some chemotherapies cause diarrhea. The findings could be the basis for developing new treatments for patients with cancer who develop gastrointestinal side effects from chemotherapy. A new study has linked age with how well patients with melanoma responded to treatment with immune checkpoint inhibitors.
Experiments in mice suggested that the response pattern may be due to an age-related shift in the kinds of immune cells in tumors. The NCI Experimental Therapeutics NExT program works with researchers and top scientific experts to advance promising or novel cancer therapies from the earliest stages of research to human clinical trials.
As the patents on some widely used drugs to treat cancer expire in the coming years, biosimilar drugs are being developed for the treatment of patients with cancer. Are biosimilars effective and will they expand treatment options for patients? A novel approach to immunotherapy developed by NCI researchers has led to the complete regression of breast cancer in a patient who was unresponsive to all other treatments.
The findings were published in Nature Medicine. Findings from three arms were released at the ASCO annual meeting, adding to findings from one arm released in Two independent groups of researchers have fused a TGF-beta receptor to a monoclonal antibody that targets a checkpoint protein.
The result is a single hybrid molecule called a Y-trap that blocks two pathways used by tumors to evade the immune system. Initial results from a series of three small clinical trials of a targeted cancer therapy called larotrectinib suggest that it may be effective in patients—children and adults—with a wide variety of cancer types.
Two compounds that target components of the circadian clock killed several types of cancer cells in the lab and slowed the growth of brain tumors in mice without harming healthy cells, a new study showed. A small but growing number of patients with cancer are being treated with oncolytic viruses, which infect and kill tumor cells.
But research now suggests that these treatments also work against cancer by spurring an immune response. Using mouse models of cancer, researchers found that altering the gut microbiome could affect whether tumors responded to checkpoint inhibition.
A new study has found the commonly used chemotherapy drug cisplatin is retained in the inner ear of mice and humans for long periods. The finding may explain why many patients treated with the drug develop hearing loss and could point toward potential ways to prevent it. Joint pain caused by aromatase inhibitors in postmenopausal women with breast cancer can cause some women to stop taking the drugs.
Reducing their symptoms may translate into better adherence to therapy. CAR T-cell therapy is a rapidly emerging form of cancer treatment, primarily for blood cancers like leukemia and lymphoma.
An article about research to improve CAR T-cell therapy and expand its use. People with HIV are often excluded from clinical trials to protect their safety. Preliminary results from an NCI-sponsored study of an immunotherapy drug show that people with HIV can safely participate in clinical trials. Research studies show tests that analyze tumor DNA in blood, called liquid biopsies, may help detect cancer early, guide precision cancer treatment, and track treatment response.
When given at the same time, two immune checkpoint inhibitors were ineffective against breast cancer growth in mice, a new study found. The combination was more effective and safer if the two inhibitors were given in a specific sequence. In a large study, patients with nonmetastatic breast, lung, or colorectal cancer who chose alternative therapies had substantially worse survival than patients who received conventional cancer treatments.
A new study conducted primarily in mice suggests that chemotherapy given before surgery for breast cancer can cause changes in cells in and around the tumor that are tied to an increased risk of the cancer spreading to other areas of the body. A drug used to treat several blood cancers, ibrutinib, has been approved by FDA to treat chronic graft-versus-host disease, making it the first approved therapy for this potentially fatal side effect of cancer-related stem cell transplants.
The FDA has cleared a cooling cap—a device designed to reduce hair loss during chemotherapy called the DigniCap Scalp Cooling System—for use by patients with any type of solid tumor. Researchers who study exceptional responders—patients who have dramatic and long-lasting responses to treatments for cancer that were not effective for most similar patients—met recently to discuss the state of the science in this emerging field. FDA approved pembrolizumab for patients with solid tumors that have specific genetic features, called mismatch repair deficiency and high microsatellite instability.
This is the first approval based on a genetic feature, rather than cancer type. Cancer patients, even those who are undergoing difficult treatments, are willing to devote time to completing thorough assessments of the side effects they encounter in clinical trials, a new study finds.
Researchers have used adult stem cells to create a tool for ranking how toxic a group of cancer drugs, called tyrosine kinase inhibitors, are to human heart cells. Such a test could potentially identify toxic side effects earlier in the drug development process.
Using a new tool for editing genomes, known as CRISPR, researchers have genetically engineered immune cells and improved the ability of these cells to kill cancer cells in mice.
In experiments in mice, researchers show platelets linked to an immunotherapy drug can help eliminate residual cancer cells that remain after surgery. The engineered platelets may also prevent leftover cancer cells from spreading.
Cancer Research UK is to overhaul its brand and marketing strategy to embed a direct response call to its audience via all its future communications. The new strategy, which comes following the.
Discover the latest information on cancer research. Stay updated with facts about groundbreaking research on treatment, prevention and early detection.
Cancer Research UK, amongst others, have embraced web and taken the initiative to promote online activities particularly through user forums, blogs and. Further research in oncology drugs market especially personalized medicines approach could be highly fruitful to find the effective treatment solutions to various cancer types. Patent expiration for the key cancer drugs has significantly increased the scope of economic biosimilar across developing regions, where the prevalence of cancer is at peak.
At Cancer Research UK we pioneer research to bring forward the day when all cancers are cured. With no government funding, our progress depends on your donations. Cancer Research UK is making a break from the usual charity communications with a campaign that uses real footage to show the day-to-day life of people affected by cancer and how its work can help bring about a time when no one will die from the disease. The ‘Right Now’ campaign, created by.